Chemistry:TNP-470

From HandWiki
TNP-470
TNP-470 structure.png
Names
Preferred IUPAC name
[(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] N-(2-chloroacetyl)carbamate
Other names
TNP-470, O-(chloroacetylcarbamoyl)fumagillol
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
DrugBank
EC Number
  • 663-348-8
UNII
Properties
C19H28ClNO6
Molar mass 401.88 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
Tracking categories (test):

TNP-470 is an methionine aminopeptidase 2 inhibitor. Although it was one of the first angiogenesis inhibitor tested in clinical trials, its potential was hampered by neurotoxic effects and lack of effectiveness.[1][2][3]

References

  1. Goya Grocin, Andrea; Kallemeijn, Wouter W.; Tate, Edward W. (October 2021). "Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity". Trends in Pharmacological Sciences 42 (10): 870–882. doi:10.1016/j.tips.2021.07.004. PMID 34446297. 
  2. Kruger, E. A.; Figg, W. D. (June 2000). "TNP-470: an angiogenesis inhibitor in clinical development for cancer". Expert Opinion on Investigational Drugs 9 (6): 1383–1396. doi:10.1517/13543784.9.6.1383. ISSN 1354-3784. PMID 11060750. https://pubmed.ncbi.nlm.nih.gov/11060750/. 
  3. Stadler, Walter M.; Kuzel, Timothy; Shapiro, Charles; Sosman, Jeffery; Clark, Joseph; Vogelzang, Nicholas J. (August 1999). "Multi-Institutional Study of the Angiogenesis Inhibitor TNP-470 in Metastatic Renal Carcinoma" (in en). Journal of Clinical Oncology 17 (8): 2541–2545. doi:10.1200/JCO.1999.17.8.2541. ISSN 0732-183X. PMID 10561320. https://ascopubs.org/doi/10.1200/jco.1999.17.8.2541.